Free Trial

Hims & Hers Health (HIMS) Stock Forecast & Price Target

Hims & Hers Health logo
$55.48 +3.72 (+7.19%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$54.98 -0.50 (-0.91%)
As of 09/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
3
Hold
8
Buy
2

Based on 13 Wall Street analysts who have issued ratings for Hims & Hers Health in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 13 analysts, 3 have given a sell rating, 8 have given a hold rating, and 2 have given a buy rating for HIMS.

Consensus Price Target

$38.92
-29.85% Downside
According to the 13 analysts' twelve-month price targets for Hims & Hers Health, the average price target is $38.92. The highest price target for HIMS is $68.00, while the lowest price target for HIMS is $26.00. The average price target represents a forecasted downside of -29.85% from the current price of $55.48.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HIMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hims & Hers Health and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Analyst Ratings Over Time

TypeCurrent Forecast
9/14/24 to 9/14/25
1 Month Ago
8/15/24 to 8/15/25
3 Months Ago
6/16/24 to 6/16/25
1 Year Ago
9/15/23 to 9/14/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
8 Buy rating(s)
Hold
8 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$38.92$39.83$38.00$19.86
Forecasted Upside-29.85% Downside-13.57% Downside-36.51% Downside19.84% Upside
Consensus RatingReduceReduceHoldModerate Buy

HIMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HIMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hims & Hers Health Stock vs. The Competition

TypeHims & Hers HealthMedical CompaniesS&P 500
Consensus Rating Score
1.92
2.78
2.53
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside-29.85% Downside17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent HIMS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/12/2025Canaccord Genuity Group
2 of 5 stars
Maria Ripps
Maria Ripps
2 of 5 stars
Reiterated RatingBuy$68.00+31.32%
8/19/2025Zacks Research
0 of 5 stars
 DowngradeStrong-BuyHold
8/18/2025Truist Financial
3 of 5 stars
Jailendra Singh
Jailendra Singh
Not Rated
Lower TargetHold$48.00 ➝ $37.00-17.43%
8/5/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
6/23/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
6/23/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$30.00-27.54%
6/11/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingEqual Weight$40.00-28.11%
5/7/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold
5/6/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$35.00 ➝ $39.00-7.01%
4/29/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetUnderperform$22.00 ➝ $26.00-28.33%
4/29/2025TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$44.00 ➝ $30.00+5.23%
2/25/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$24.00 ➝ $40.00+3.32%
1/7/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$35.00+30.50%
8/9/2024Imperial Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformIn-Line
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetHold$14.00 ➝ $23.00+19.98%
4/26/2024Seaport Res Ptn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
2/27/2024Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$15.00 ➝ $17.00+22.83%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
1/5/2024Tigress Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$14.00 ➝ $15.00+81.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:40 PM ET.


HIMS Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Hims & Hers Health is $38.92, with a high forecast of $68.00 and a low forecast of $26.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 sell ratings, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" HIMS shares.

According to analysts, Hims & Hers Health's stock has a predicted downside of -29.85% based on their 12-month stock forecasts.

Over the previous 90 days, Hims & Hers Health's stock had 1 downgrade by analysts.

Hims & Hers Health has been rated by research analysts at Canaccord Genuity Group, Citigroup, Needham & Company LLC, Truist Financial, UBS Group, and Zacks Research in the past 90 days.

Analysts like Hims & Hers Health less than other "medical" companies. The consensus rating for Hims & Hers Health is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HIMS compares to other companies.


This page (NYSE:HIMS) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners